Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report

Pulmonary pleomorphic carcinoma (PPC) is well-known for its aggressive nature that is usually resistant to platinum-based chemotherapy. On the other hand, the efficacy of an immune checkpoint inhibitor-based regimen in PPC has been elucidated. PPCs harboring epidermal growth factor receptor (EGFR) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kano, Yukari, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tsutsumi, Rei, Sato, Izumi, Tanimura, Mai, Nakano, Takayuki, Tanimura, Keiko, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227213/
https://www.ncbi.nlm.nih.gov/pubmed/35743969
http://dx.doi.org/10.3390/medicina58060706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227213/
https://www.ncbi.nlm.nih.gov/pubmed/35743969
http://dx.doi.org/10.3390/medicina58060706

Ejemplares similares